"2026-01-02 17:52:51","AXSM","178.69","9","$4.2B","6.62","168.77","198.54","FDA acceptance of sNDA for AXS-05 (Alzheimer's Agitation) with Priority Review accelerates commercial timeline to April 2026, significantly de-risking the asset.","OPEN"
"2026-01-02 17:52:53","CORT","38.2","8","$4.8B","6.38","28.63","57.33","FDA approval of Relacorilant for hypercortisolism solidifies Corcept's endocrinology franchise and removes a major overhang.","OPEN"
"2026-01-02 17:52:54","VNDA","8.25","7","$521M","0.61","7.33","10.08","Approval of Tradipitant for motion sickness creates a new niche revenue stream, validating the pipeline after previous setbacks.","OPEN"
